DOCSLIB.ORG

Mortality of Patients with Rheumatoid Arthritis Requiring Intensive Care: a Single-Center Retrospective Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mortality of Patients with Rheumatoid Arthritis Requiring Intensive Care: a Single-Center Retrospective Study Clinical Rheumatology (2019) 38:3015–3023 https://doi.org/10.1007/s10067-019-04651-w ORIGINAL ARTICLE Mortality of patients with rheumatoid arthritis requiring intensive care: a single-center retrospective study Yael Haviv-Yadid1 & Yulia Segal2 & Amir Dagan3,4,5 & Kassem Sharif6 & Nicola Luigi Bragazzi7 & Abdulla Watad6 & Howard Amital6,8,9 & Yehuda Shoenfeld8,9,10,11 & Ora Shovman6,8,9 Received: 20 February 2019 /Revised: 10 June 2019 /Accepted: 18 June 2019 /Published online: 26 June 2019 # International League of Associations for Rheumatology (ILAR) 2019 Abstract Background Patients with rheumatoid arthritis (RA) are at a high risk for life-threatening conditions requiring admission to the intensive care unit (ICU), but the data regarding the outcomes of these patients is limited. The present study investigated the clinical characteristics and outcomes of RA patients admitted to an ICU. Methods This retrospective cohort study included RA patients admitted to the general ICU of the Sheba Medical Center during 2002–2018. The main outcome was 30-day mortality. Using Student’s t test, χ2, and multivariable analyses, we compared the demographic, clinical, and laboratory parameters of the survivors and the non-survivors. Figures with p value < 0.05 were considered statistically significant. Results Forty-three RA patients were admitted to the ICU during the study period (mean age, 64.0 ± 13.1 years; 74.4% female). The leading causes of ICU admission were infection (72.1%), respiratory failure (72.1%), renal failure (60.5%), and septic shock (55.8%). The 30-day mortality rate was 34.9%, with infection (9/15, 60%) as the most frequent cause. The mean Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores were 19.7 ± 12.5 and 7.0 ± 4.5, respec- tively. Multivariable analysis showed that heart failure (p = 0.023), liver failure (p = 0.012), SOFA score (p = 0.007), and vasopressor treatment in ICU (p = 0.039) were significantly associated with overall mortality. SOFA score was linked with overall mortality (area under the curve (AUC) = 0.781 ± 0.085, p = 0.003) and mortality from respiratory failure (AUC = 0.861 ± 0.075, p = 0.002), while APACHE II score was only correlated with mortality from infection (AUC = 0.735 ± 0.082, p = 0.032). Conclusions Our study demonstrated a relatively high mortality rate among RA patients who were admitted to the general ICU. RA patients with risk factors such as heart failure, liver failure, elevated SOFA score, and vasopressor treatment in ICU should be promptly identified and treated accordingly. Key Points • The 30-day mortality rate of patients with RA that were admitted to the general ICU of a tertiary hospital was 34.9%. • The most common causes of ICU admission among patients with RA were infections and respiratory failure. Infections were the most common cause of death among these patients. • Patients with RA that present to the ICU with heart failure, liver failure, elevated SOFA score, and/or require vasopressor treatment in ICU should be promptly identified and treated accordingly. * Ora Shovman 7 School of Public Health, Department of Health Sciences (DISSAL), [email protected] University of Genoa, Genoa, Italy 1 Intensive Care Unit, Sheba Medical Center, Ramat Gan, Israel 8 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, 52621 Ramat Gan, Israel 2 Department of Internal Medicine ‘T’, Sheba Medical Center, Ramat Gan, Israel 9 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 3 Department of Internal Medicine ‘B’, Assuta Ashdod Medical Center, Ashdod, Israel 10 Past incumbent of the Laura Schwarz-Kipp Chair for Research of 4 Rheumatology Unit, Assuta Ashdod Medical Center, Ashdod, Israel Autoimmune Diseases, Tel Aviv University, Tel Aviv, Israel 5 Ben-Gurion University of the Negev, Beer Sheva, Israel 11 I.M. Sechenov First Moscow State Medical University of the 6 Department of Internal Medicine ‘B’, Sheba Medical Center, Ramat Ministry of Health of the Russian Federation (Sechenov University), Gan, Israel Moscow, Russia 3016 Clin Rheumatol (2019) 38:3015–3023 Keywords Acute physiology and chronic health evaluation (APACHE) II score . Intensive care unit . Rheumatoid arthritis mortality . Sequential organ failure assessment (SOFA) score Introduction Material and methods Patients with autoimmune rheumatic disorders (ARDs) are at Population high risk for complications requiring admission to the inten- sive care units (ICUs) [1, 2]. The prevalence of different This is a single-center observational retrospective study con- ARDs in ICUs has changed in the past decades, and systemic ducted in the general ICU of the Sheba Medical Center in lupus erythematosus (SLE) has surpassed rheumatoid arthritis Tel-Hashomer, a tertiary referral hospital in Israel. Using com- (RA) as the leading autoimmune disease necessitating admis- puterized ICU discharge summaries, we analyzed the medical sion to ICU [1]. However, RA remains the second most prev- records of 43 patients who have fulfilled the American College alent ARD in ICUs and represents a challenge for the physi- of Rheumatology (ACR) 1987 or ACR 2010 criteria for RA cians. The majority of previous studies on ARDs patients in and were admitted to the general ICU during 2002–2018. RA ICUs analyzed mixed cohorts of patients with different dis- patients who were admitted to the other ICUs of the hospital eases that have distinct courses, mortality rates, and mortality- such as the cardiac, neurological, or pediatric ICUs were not associated factors. This heterogeneity in cohorts may partially included. The study fulfilled the ethical guidelines of the most explain the significant variability in the reported mortality recent declaration of Helsinki (Edinburgh, 2000) and received rates that range from 17 to 55%, and the wide spectrum of approval (No. 3233-16-SMC) by the local ethical committee. variables that may be associated with increased mortality [1]. Data regarding patient demographics (age and gender) and To date, few retrospective studies have investigated the clinical and laboratory parameters were obtained retrospec- clinical aspects and the prognostic features of RA patients in tively from patient charts and laboratory records. Among ICU [3–6]. One of these studies is a large population-based those who were admitted twice to the ICU, only the first ad- study from Canada which demonstrated that RA patients had a mission was considered. In addition, data regarding the overall higher risk for ICU admission in comparison with the general mortality rate in the general ICU was extracted from the com- population (HR 1.65; 95% CI 1.50–1.83) [3]. According to puterized records of Sheba Medical Center in Tel-Hashomer. this study, during 2000–2010, the yearly ICU admission rate The severity of the disease was assessed within 24 hours of RA patients was 1%, with a 10-year cumulative rate of 8%, after ICU admission using the “Acute Physiology and a figure that was 60% higher compared with that in the general Chronic Health Evaluation II” (APACHE II) [11] and the population. The most frequent reasons for ICU admission “Sequential Organ Failure Assessment” (SOFA) [12]scores. were ischemic heart disease (IHD) followed by infections [3]. The APACHE II score is calculated based on the age of the In the last decades, several therapeutic advancements have patient and 12 routine physiological measurements, including been achieved in the management of RA, and this led to a alveolar-arterial oxygen difference (AaDO2) or partial pressure decreasing mortality rate for the last 50 years [7]. Despite this, of oxygen in arterial blood (PaO2), depending on the fraction of RA patients still have a higher mortality risk compared with the inspired oxygen (FiO2), rectal temperature, mean arterial that in the general population [7]. With regard to the ICU pressure, arterial pH, heart rate, respiratory rate, serum sodium mortality rate, the data is relatively limited. In the Canadian and potassium, creatinine, hematocrit, white blood cell count, study [3], the mortality rate found in the RA cohort was not and Glasgow coma scale [11]. A score of 25 represents a pre- different from that in the general population admitted to the dicted mortality of 50% in the general ICU. The SOFA score is ICU. Another work from Israel investigated the 30-day sur- calculated using objective measures of organ dysfunction or vival rate of patients hospitalized in the ICU following sepsis failure in major organ systems, including respiratory, renal, car- and found that the mortality rate within the RA subgroup was diovascular, neurologic, liver, and coagulation systems. The 51.2%, similar to non-RA patients [6]. Previous studies have SOFA score ranges from 0 to 24, and higher scores predict described the course and the outcome of dermatomyositis, worse outcomes and higher mortality rates [12]. scleroderma, and vasculitis patients admitted to the general Mortality was defined as death within 30 days of ICU ad- ICU of a tertiary hospital in Israel [8–10]. The objective of mission. Survival was defined as being successfully trans- the current study is to analyze the clinical characteristics of ferred from the ICU into another department and either sur- RA patients admitted to the ICU between 2002 and 2018, to viving until day 30 in the hospital or being released from the investigate their clinical course and outcome, and to identify hospital and then having another medical entry recorded into
Load more

Recommended publications
  • Therapeutic Hypothermia for Comatose Patients: VF Versus Other Initial Rhythm – Does It Matter?
    P13 - Posters - Intensive Cardiac Care Therapeutic Hypothermia for Comatose Patients: VF Versus Other Initial Rhythm – does it Matter? Avishag Laish-Farkash, Shlomi Matetzky, Samer Kassem, Alon Barsheshet, Hanny Haj-Iahia, Nataliya Ulanovsky, Hanoch Hod Heart Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 339 P13 - Posters - Intensive Cardiac Care The Value of Troponin-I Curve after Primary PCI for ST Elevation Myocardial Infarction Avishag Laish-Farkash 1,3, Hanoch Hod 1,3,Ben-Ami Sela2,3,Yoram Amsalem1,3, Athanasios Michailidis 1, Shlomi Matetzky 1,3 1 Heart Institute, 2 Institute for Chemical Pathology, Sheba Medical Center, Tel Hashomer, 3 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 340 P13 - Posters - Intensive Cardiac Care C-Reactive Protein as a Predictor of Active Coronary Disease and Worse Prognosis in Chest Pain Unit Dan Oieru 1,Roy Beigel1, Hanoch Hod 1,2, Pierre Chouraqui 1,2,Orly Goitein1, Eli Konen 1, Roy Beinart 1,Paul Fefer1,Ben-Ami Sela3,Ari Shamiss4,Jacob Or5, Shlomi Matetzky 1,2 1 Heart Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 3 Biochemical Laboratory, 4 Hospital Director, 5 Emergency Department, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 341 P13 - Posters - Intensive
    [Show full text]
  • Antibiotic Treatment for Invasive Listeriosis and Patient
    Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality.
    [Show full text]
  • APF Newsletter, Winter 2006 – 2007
    Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PeterPen) ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-040210 Article Type: Protocol Date Submitted
    [Show full text]
  • Neuro-Ophthalmology in Israel
    Worldwide Neuro-Opthalmology Section Editor: Kathleen B. Digre, MD Neuro-Ophthalmology in Israel Ruth Huna-Baron, MD, Eitan Zvi Rath, MD FIG. 1. Pioneers of neuro-ophthalmology in Israel. euro-ophthalmology was introduced in Israel during challenge of the rapid development of new and expensive N the late 1970s by Riri Manor, Yochanan Goldhammer, diagnostic and therapeutic modalities, a committee of the and Isaac Gutman (Fig. 1). They trained with from William Ministry of Health each year announces new technologies Hoyt, Lawton Smith, and Myles Behrens, respectively. These and therapies to be included in basic health coverage. There pioneers trained many local ophthalmologists, neurologists, are 18 magnetic resonance imaging devices in Israel and 5 and neuro-ophthalmologists in Israel, and their efforts resulted interventional neurovascular units, and most medical in 21 neuro-ophthalmologists currently serving a population centers in the country have a neuro-ophthalmology service of 8 million. Many Israeli neuro-ophthalmologists did fellow- (Table 1). Much like in the United States, referrals come ships in the United States with a variety of other mentors, from neurologists, ophthalmologists, neurosurgeons inter- including Ronald Burde, Joel Glaser and Norman Schatz, ventional neuroradiologists, and endocrinologists. Mark Kupersmith, Byron Lam, Neil Miller, Barry Scarf, In 1997, the Israeli Neuro-Ophthalmology Society was and Jonathan Trobe. founded by Ririo Manor as a subspecialty section of the In Israel, each citizen is entitled to health care services Israeli Ophthalmology Society. Two annual meetings are under the National Health Insurance Law. To meet the organized by the society, of which one hosts a leading TABLE 1.
    [Show full text]
  • Israeli Cardio-Oncology Society Virtual Meeting Preliminary Program
    January 13-14, 2021 | Virtual Conference TOWARDS A COMPREHENSIVE CARDIAC-CANCER CARE Take this unique opportunity to join the ISCO 2021 conference and to effectively reach hundreds of cardiologists, oncologists and hemato-oncologists. Join us and present your research and technology to this influential and knowledgeable audience, and to have full access to all networking benefits. Conference secretariat - Dirigo Events & Conferences 3 Menorat Hamaor st. Tel-Aviv, Israel For more information, please contact: Tel: 03-7775485 | Email: [email protected] Yael Ziv Project Manager – Industry Liaison, Dirigo | Mobile: +972-54-5599821 | Email: [email protected] ISRAELI CARDIO-ONCOLOGY SOCIETY VIRTUAL MEETING PRELIMINARY PROGRAM Platinum Sponsorship Gold Sponsorship Silver Sponsorship January 13, 2021 15:45-16:00 Opening Session 15:45-15:47 Zaza Iakobishvili, Founder and Chair of the Meeting, Cardiology 15:47-15:49 Dan Gilon, Chair of the Meeting, Cardiology 15:49-15:51 David Sarid, Chair of the Meeting, Oncology 15:51-15:53 Martin Ellis, Chair of the Meeting, Hematology 15:53-15:55 Alex Lyon, ESC Cardio-Oncology Council 15:55-15:57 Bonnie Ky, JACC Cardio-Oncology 16:00-17:00 Plenary Session Chairs: Giorgio Minnotti, Faculty of Medicine and Surgery, Campus Bio-Medico University of Rome, Italy Alexander Battler, Chairman, Advisory Council on Cardiovascular Disease Management and Prevention, Ministry of Health, Israel 16:00-16:20 How to establish Cardio-Oncology collaboration Susan F. Dent, Associate Director of Breast Cancer Clinical Research, Co-Director Duke Cardio-Oncology Program, Durham, NC, USA 16:20-16:40 Guidelines in Cardio-Oncology: Gaps and Opportunities José Luis Zamorano, University Hospital Ramon Y Cajal, Madrid, Spain 16:40-17:00 Panel discussion: Future of Cardio-Oncology Richard H.
    [Show full text]
  • Phrenic Nerve Paralysis After Pediatric Cardiac Surgery: Role of Diaphragmatic Plication
    S2 - Ami Cohen Award Competition and Pediatric Cardiac Surgery Phrenic Nerve Paralysis after Pediatric Cardiac Surgery: Role of Diaphragmatic Plication Michael Katz 1,Uriel Katz2, Sion Houri 3,Hagi Dekel1, Akiva Tamir 2, Alona Raucher Sternfeld 2, Ilan Cohen 3, Michaela Witzling 4, Eli Hauptman 1,Lior Sasson1 1 Cardiothoracic Surgery, 2 Heart Institute, Pediatric Cardiology Unit, 3 Pediatric ICU, 4 Radiology, E. Wolfson Medical Center affiliated with the Sackler School of Medicine, Tel Aviv University, Holon, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 11 S2 - Ami Cohen Award Competition and Pediatric Cardiac Surgery Ligation of Patent Ductus Arteriosus for Premature Infants in the Intensive Care Units in the North of Israel Victor Rubchevsky, Dan Aravot, Tammah Safadi Cardiothoracic Surgery, Carmel Hospital, Haifa, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 12 S3 - Acute Coronary Syndromes Impact of Red Blood Cell Transfusion on Clinical Outcomes in Patients with Acute Myocardial Infarction Doron Aronson, Miry Blich, Michael Kapeliovich, Rafael Beyar, Walter Markiewicz, Haim Hammerman Cardiology, Rambam Medical Center, Haifa, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 13 S3 - Acute Coronary Syndromes Is the Increased Use of Coronary Angiography in Acute Coronary Syndromes Accompanied by a Survival Benefit? David Harpaz 1,2, Yoseph Rozenman 1,2,3, Valentina Boyko 2, Solomon Behar 2,3, Shmuel Gottlieb 2,3 1 The Heart Institute Holon, E. Wolfson Medical Center, Holon, 2 The Neufeld
    [Show full text]
  • Diagnostic Criteria in Autoimmune Diseases
    Diagnostic Criteria in Autoimmune Diseases Diagnostic Criteria in Autoimmune Diseases Yehuda Shoenfeld Tel-Aviv University, Tel-Aviv, Israel Ricard Cervera University of Barcelona, Barcelona, Catalonia, Spain M. Eric Gershwin University of California at Davis, Davis, CA, USA Editors With compliments of Editors Prof. Yehuda Shoenfeld Prof. Ricard Cervera Sheba Med. Center Hospital Clinic Dept. Medicine ‘‘B’’ Servei de Malalties 52 621 Tel-Hashomer Autoimmunes Israel Villarroel, 170 [email protected] 08036 Barcelona Catalonia, Spain [email protected] Prof. M. Eric Gershwin University of California at Davis School of Medicine Division of Rheumatology, Allergy, and Clinical Immunology Davis, CA 95616 USA [email protected] ISBN: 978-1-60327-284-1 (softcover) e-ISBN: 978-1-60327-285-8 ISBN: 978-1-60327-427-2 (hardcover) DOI: 10.1007/978-1-60327-285-8 Library of Congress Control Number: 2008933364 # 2008 Humana Press, a part of Springer Science+Business Media, LLC All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, 999 Riverview Drive, Suite 208, Totowa, NJ 07512 USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.
    [Show full text]
  • APF H N P D N a F R C I I E R
    Winter 2011-2012 sicians y a APF h n P d n a F r c i i e r n e A Newsletter of the d m s News American Physicians and Friends A for Medicine in Israel APF - Supporters of Medicine in Israel 2001 Beacon Street, Suite 210, Boston, MA 02135 617-232-5382 [email protected] From the President 2. The Fellowship Awards Program Since 1950 APF has awarded over 1500 fellowship awards totaling over $4 million. As I’ve indicated in past columns, if one looks at the past and current roster of leaders of Israeli medicine, the vast majority of them have been APF fellows in the past. 3. The Student Programs Under the very able leadership of Drs. Alan Menkin and Charles Kurtzer each year up to 40 North American medical It has been a pleasure and an honor to students have gone to Israel for 10 days serve as APF President from 2006 to under the joint sponsorship of Taglit/ 2011. As my term of office draws to a birthright. This has included two days of close I would like to highlight some of the activities with the Israel Defense Force important events of the past five years. Medical Corps, The Israeli Ministry of Health, and the Computer Simulation 1. Emergency Medical Volunteer (EMV) Center at Tel HaShomer Hospital. Courses and Registry In the last five years the EMV Registry 4. Corporate Membership has become fully operational. Working in Under the visionary leadership of Dr. close association with the Israeli Defense Paul Scherer, APF now has Corporate Forces Medical Corps and The Ministry Members and we are grateful for their of Health we now have records of over continued support.
    [Show full text]
  • Cardiovascular Device Infections
    The Cyprus CARDIOVASCULAR DEVICE INFECTIONS PROGRAM 10.9.2019 Crowne Plaza CityCenter Azrieli, Tel-Aviv 08:00-08:20 Coffee and Registration 08:20-08:30 Greetings 08:30-10:00 First Session: Diagnosis and Management of Infective Endocarditis Chairs: Yasmin Maor, Edith Wolfson Medical Center, Holon, Israel Ran Nir- Paz, Hadassah Medical Center, Jerusalem, Israel 08:30-08:50 Bartonella species, a common but often missed cause of blood-culture-negative endocarditis Michael Giladi, the Infectious Disease Unit, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 08:50-09:20 Imaging of Endocarditis and the Role of Imaging in Diagnostics Gilbert Habib, La Timone Hospital, Marseille, France 09:20-09:40 Timing of surgery for complicated infective endocarditis Jacob Strahilevitz, Hadassah Medical Center, Jerusalem, Israel 09:40-10:00 Effect of surgical treatment for infective endocarditis on in-hospital mortality rate: Hadassah experience Sarah Israel, Hadassah Medical Center, Jerusalem, Israel 10:00-10:30 Coffee break 10:30-12:30 Second Session: Procedural Considerations and Treatment of Endocarditis/CIED Infection Chairs: Mahmoud Suleiman, Rambam Health Care Campus, Haifa, Israel Leonid Sternik, Sheba Medical Center, Tel Hashomer, Israel 10:30-11:00 The role of the antibiotic envelope Mauro Biffi, S.Orsola Malpighi Hospital, Bologna, Italy 11:00-11:30 Management of Embolic Events in Endocarditis Gilbert Habib, La Timone Hospital, Marseille, France 11:30-11:45 A 100 year old frail lady with
    [Show full text]
  • 1. Personal Details 2. Academic Education
    Avishag Laish-Farkash, MD, PhD 1 CURRICULUM VITAE AND LIST OF PUBLICATIONS 1. Personal Details Family name, first name: Laish-Farkash Avishag Date and place of birth: 28 April 1970, Israel Address (Office): Arrhythmia and Pacing Unit, Cardiology department, Assuta Ashdod University Medical Center, Ashdod (Residence): 5 Haavoda street, Givat-Shmuel 5402309, Israel Telephone number (Residence): 077-7897808 Cellular phone number: 053-7678726 Fax number: (home) 03-751-5494 E-mail address: [email protected]; [email protected] 2. Academic Education B.Sc. Med Sackler School of Medicine, Tel-Aviv University, Israel Date award: 8.1991 M.D. degree Sackler School of Medicine, Tel-Aviv University, Israel Date award: 6.1996 Title of M.D. Thesis: “The Natural Course of Erythrocyte Sedimentation Rate and Non-Specific Acute Phase Reactants after Cardiac Surgery”. Names of Supervisors: Meir Lahav, M.D., Medicine Department E, Sapir Medical Center, Kfar-Saba, and Arie Regev, M.D., Medicine Department E, Beilinson Campus, Rabin Medical Center, Petach-Tiqva. Ph.D. Sackler School of Medicine, Tel-Aviv University, Israel Date award: 2/2004 Title of Ph.D. Thesis: “Congenital Long QT Syndrome: Molecular and Electrophysiological Evaluation of a New SCN5A Mutation in a Large Israeli Pedigree”. Names of Supervisors: Prof. Michael Eldar, M.D., Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, and Prof. Ilana Lotan, Ph.D., The Avishag Laish-Farkash, MD, PhD 2 Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University. 3. Professional Training 1.1.95 –31.12.95 Internship, Beilinson campus, Rabin Medical Center, Petach-Tiqva, Israel.
    [Show full text]
  • Posters - Interventional Cardiology
    P1 - Posters - Interventional Cardiology The Use of Drug Eluting Stents in Regular Clinical Practice did not Reduce the Clinical Restenosis Rate Compared to Bare Metal Stents. Diab Ghanim, Farid Naoom, Aviva Peleg, Yonathan Hasin Cardiovascular, Cardiology Department, Baroch Padeh Hospital, Tiberias, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 229 P1 - Posters - Interventional Cardiology The Impact of Diabetes Mellitus on Drug Eluting Stents Outcomes at One-year Following Acute ST Elevation Acute Myocardial Infarction Itsik Ben-Dor, Abid Assali, Hana Vaknin-Assa, Shmuel Fuchs, Eldad Rechavia, David Brosh, Eli Lev, Alexander Battler, Ran Kornowski Cardiology, Rabin Medical Center, Petach Tikva, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 230 P1 - Posters - Interventional Cardiology Urgent Coronary Catheterization in the Daily Practice: Indications and Changes Over 10 Years Khalid Suleiman, Alexander Feldman, Nahum Freedberg, Dante Antonelli, Limor Ilan- Bushari, Lev Bloch, Yoav Turgeman Heart Institute, Catheterizaion Unit, Ha'Emek Medical Center, Afula, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 231 P1 - Posters - Interventional Cardiology Late Drug Eluting Stent Thrombosis: Clinical, Angiographic and Intravascular Ultrasound Characteristics Khalid Suleiman, Limor Ilan- Bushari, Alexander Feldman, Yoav Turgeman Heart Institute, Catheterization Unit, Ha'Emek Medical Center, Afula, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 232 P1 - Posters - Interventional Cardiology
    [Show full text]